NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Baxter International Inc. BAX
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$11.2B
▲ 5.7% vs FY2024
EPS · FY25
$-1.87
Dividend / sh · FY25
$0.52
Payout · FY25
-36%
ROE · FY25
-14.6%
Net margin · FY25
-8.5%
Dividend coverage
-3.6×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 11.2B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 9 cents on every revenue dollar this year.
Per share
USD -1.87
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
-14.6%
Return on equity, FY2025
ROE
Operating margin-2.7%
Net margin-8.5%
Return on assets-4.2%
Each USD of equity lost 15 cents this year.
Returned to shareholders
USD 348.0M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 348.0M
Net buybacks—
Share of profit-36.4%
Consecutive raises—
USD 348.0M in dividends went back to shareholders in a year without profit.
Growth
−0.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+3.8%
−0.7%
+1.2%
−0.9%
Dividend / share
−23.2%
−11.4%
−8.5%
−5.3%
Returned to shareholders
−16.8%
−18.6%
−9.2%
−11.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 20.1B
total assets, end of FY2025
Total assetsUSD 20.1B
EquityUSD 6.1B
CashUSD 2.0B
Gross debtUSD 9.4B
Net debtUSD 7.5B
Current ratio2.31×
Net debt stands at 122% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
11.2
10.6
10.4
10.1
12.1
11.7
11.4
11.1
10.6
10.2
10.0
10.7
9.4
13.9
13.9
12.8
12.6
12.3
11.3
Operating income $B
−0.3
0.0
0.7
−2.8
1.4
1.6
1.8
1.6
1.3
0.7
0.4
0.7
0.5
2.9
2.8
1.9
2.7
·
·
EBITDA $B
0.7
1.0
1.7
−1.8
2.2
2.4
2.6
2.4
2.0
1.5
1.2
1.4
1.1
3.6
3.5
2.6
3.4
·
·
Income tax $B
0.4
0.0
0.1
−0.1
0.1
0.2
−0.0
0.1
0.5
−0.0
0.0
0.0
0.1
0.6
0.6
0.5
0.5
0.4
0.4
Net income $B
−1.0
−0.6
2.7
−2.4
1.3
1.1
1.0
1.5
0.6
5.0
1.0
2.5
2.0
2.3
2.2
1.4
2.2
2.0
1.7
EPS, diluted $
−1.87
−1.27
5.23
−4.83
2.53
2.13
1.93
2.83
1.08
9.01
1.76
4.56
3.66
4.18
3.88
2.39
3.59
3.16
2.61
Dividend / sh $
0.52
1.04
1.16
1.15
1.08
0.95
0.85
0.73
0.61
0.51
1.27
2.05
1.92
1.57
1.26
1.18
1.07
0.91
0.72
Payout %
−36
−91
22
−24
41
43
42
24
52
5
94
44
51
35
32
48
29
27
41
ROE %
−14.6
−8.4
37.3
−32.6
14.5
13.3
12.7
18.2
6.9
57.9
11.4
30.1
26.1
34.4
33.8
20.6
32.9
32.3
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
74 of 74
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed